Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma
Public ClinicalTrials.gov record NCT01980628. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-Label, Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects With Relapsed/Refractory Marginal Zone Lymphoma
Study identification
- NCT ID
- NCT01980628
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Pharmacyclics LLC.
- Industry
- Enrollment
- 63 participants
Conditions and interventions
Conditions
Interventions
- ibrutinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2013
- Primary completion
- Jun 30, 2016
- Completion
- Oct 1, 2017
- Last update posted
- Oct 15, 2019
2013 – 2017
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site Reference ID/Investigator# 837 | Tucson | Arizona | 85719 | — |
| Site Reference ID/Investigator# 047 | Duarte | California | 91010 | — |
| Site Reference ID/Investigator# 377 | Santa Monica | California | 90095 | — |
| Site Reference ID/Investigator# 763 | West Palm Beach | Florida | 33401 | — |
| Site Reference ID/Investigator# 033 | Atlanta | Georgia | 30322 | — |
| Site Reference ID/Investigator# 370 | Chicago | Illinois | 60611 | — |
| Site Reference ID/Investigator# 195 | Detroit | Michigan | 48202 | — |
| Site Reference ID/Investigator# 350 | New Hyde Park | New York | 11042 | — |
| Site Reference ID/Investigator# 745 | New York | New York | 08724 | — |
| Site Reference ID/Investigator # 200 | New York | New York | 10065 | — |
| Site Reference ID/Investigator # 407 | New York | New York | 10065 | — |
| Site Reference ID/Investigator# 220 | Hershey | Pennsylvania | 17033 | — |
| Site Reference ID/Investigator# 348 | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01980628, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 15, 2019 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01980628 live on ClinicalTrials.gov.